AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 University of Washington Tacoma, Tacoma, Washington, United States
8 University of Washington Tacoma, Tacoma, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
16 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
18 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
19 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
20 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
21 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
22 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
ABSTRACT
Background: Acute leukemias often progress rapidly, leaving newly diagnosed or relapsed/refractory patients at risk for life-threatening infections, bleeding, and psychological stress while awaiting treatment initiation. Genomic characterization increasingly drives risk stratification to guide treatment selection. Standard next-generation sequencing (NGS) panels are reported in 7-14 days. Rapid, "real-time" genomic results would facilitate timely initiation of targeted and risk-adapted leukemia-directed therapies.
Methods: This single-center pilot trial has enrolled 16 adults with suspected or confirmed acute leukemia or related hematologic malignancies at diagnosis or relapse. The primary objective was to determine the feasibility of rapid mutation and gene rearrangement detection within 12 hours of sample receipt. The secondary objective was to obtain physician feedback regarding the potential clinical impact of this assay. Subjects were required to have ≥10% circulating or marrow blasts and WBC ≥5 x 109/L. The CRISPR-enrichment single-molecule real-time long-read sequencing (CSRL) assay used 74 CRISPR RNA (crRNA) guides to target 9 common leukemia fusion breakpoints (including PML::RARA, RUNX1::RUNX1T1, CBFB::MYH11, and BCR::ABL1) and mutations (TP53, FLT3, IDH1/2, etc.). Guides were designed to bookend fusion breakpoints or mutations, or tile regions of interest, cutting the same strand in one direction. High-molecular-weight DNA extracted from blood was processed using an amplification-free Cas9-enrichment-based library preparation protocol. Oxford Nanopore R9 flow cells and Ligation Sequencing Kit 110 were used to sequence the targeted sites. Sequencing data were analyzed in real time using the BioDepot Fusion Finder bioinformatics pipeline to identify chimeric reads. Positive results were defined as detecting three unique fusion reads. Negative results were required to have > 20x coverage over 90% of guide regions. Results were certified by a molecular pathologist. After standard, CLIA-certified cytogenetic and NGS results were available, CSRL results were reported to the treating oncologists, to avoid influencing treatment decisions with a non-CLIA-certified test. Post-reporting surveys assessed physician perception of the assay’s clinical utility.
Results: Subjects had AML (n = 12), MDS (n = 2), ALL (n = 1), and MDS/MPN-U with increased blasts (n = 1). Five of sixteen subjects (31%) were positive for gene fusions: PML::RARA (n = 3), BCR::ABL1 (n = 1), and CBFB:MYH11 (n = 1). For targeted fusion events, concordance between clinical and CSRL results was found in 100% of samples. For one patient, the CBFB::MYH11 inversion was initially missed by clinical karyotype; the CSRL assay identified a cryptic CBFB::MYH11 fusion, which was later confirmed by clinical FISH.
For fusion gene-positive samples, time from sample receipt to CSRL result ranged from 9.1 to 11.4 (median 10.5) hours compared to 65.2 to 169.3 (median 79.0) hours for clinical results. For samples with no fusion detected, sequencing was kept running for the default 72 hours, and all data were analyzed to confirm a minimum coverage of ~20x. 14 physician surveys were received at the time of this abstract. Agreement that results could influence therapeutic decisions was found in seven surveys, including strong agreement from four of five physicians treating patients with fusions detected. For the clinician caring for the patient with the cryptic CBFB::MYH11 rearrangement, survey responses noted that receiving results earlier would have impacted treatment selection due to reclassification of ELN2022 risk status. This case highlights the clinical utility of rapid detection of cryptic or complex fusion events.
Conclusions: This pilot trial shows the clinical feasibility of amplification-free, CRISPR-targeted nanopore sequencing and automated bioinformatic result reporting with rapid turnaround time for acute leukemia diagnostics. The physician feedback surveys are positive and recognize the assay’s potential to impact treatment decisions but identify the need for clinical validation and more comprehensive/integrated reporting. Ongoing work includes expanding the crRNA panel to incorporate additional fusions/mutations and allow for comprehensive genomic profiling, incorporating whole genome sequencing or adaptive sampling methods, and optimizing analysis for phasing and methylation status.